Skip to main content

Table 1 Clinical and biological characteristics of breast carcinoma according to pathological response and Neo-Bioscore

From: Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Characteristics n Pathological response Neo-Bioscore
pCRa non-pCR 0 1 2 3 4 5 6 7
310 (100%) 43 (13.8%) 267 (86.2%) 1 (0.3%) 18 (5.8%) 47 (15.2%) 84 (27.1%) 83 (26.8%) 49 (15.8%) 23 (7.4%) 5 (1.6%)
Menopausal status
 Premenopausal 148 (48%) 21 (48.8%) 127 (47.6%) 0 (0%) 10 (55.6%) 31 (66%) 42 (50.0%) 33 (39.8%) 22 (44.9%) 8 (34.8%) 2 (40%)
 Postmenopausal 162 (52%) 22 (51.1%) 140 (52.4%) 1 (100%) 8 (44.4%) 16 (34%) 42 (50.0%) 50 (60.2%) 27 (55.1%) 15 (65.2%) 3 (60%)
Histological grade
 I/II 160 (52%) 16 (37.2%) 144 (53.9%) 1 (100%) 17 (94.4%) 36 (76.6%) 61 (72.6%) 34 (41.0%) 11 (22.4%) 0 (0%) 0 (0%)
 III 150 (48%) 27 (62.8%) 123 (46.1%) 0 (0%) 1 (5.6%) 11 (23.4%) 23 (27.4%) 49 (59.0%) 38 (77.6%) 23 (100%) 5 (100%)
Estrogen receptor
 Negative 131 (42%) 32 (74.4%) 99 (37.1%) 0 (0%) 2 (11.1%) 10 (21.3%) 31 (36.9%) 43 (51.8%) 24 (49%) 16 (69.6%) 5 (100%)
 Allred 2–6 (< 70%) 40 (13%) 4 (9.3%) 36 (13.5%) 1 (100%) 4 (22.2%) 7 (14.9%) 11 (13.1%) 8 (9.6%) 8 (16.3%) 1 (4.3%) 0 (0%)
 Allred 7–8 (≥70%) 139 (45%) 7 (16.3%) 132 (49.4%) 0 (0%) 12 (66.7%) 30 (63.8%) 42 (50.0%) 32 (38.6%) 17 (34.7%) 6 (26.1%) 0 (0%)
Ki-67
  < 20% 80 (26%) 5 (11.6%) 75 (28.1%) 0 (0%) 6 (33.3%) 13 (27.7%) 27 (32.1%) 20 (24.1%) 12 (24.5%) 2 (8.7%) 0 (0%)
 20–50% 134 (43%) 18 (41.9%) 116 (43.4%) 0 (0%) 8 (44.5%) 22 (46.8%) 38 (45.2%) 35 (42.2%) 17 (34.7%) 12 (52.2%) 2 (40%)
  ≥ 50% 96 (31%) 20 (46.5%) 76 (28.5%) 1 (100%) 4 (22.2%) 12 (25.5%) 19 (22.7%) 28 (33.7%) 20 (40.8%) 9 (39.1%) 3 (60%)
HER2
 Negative 236 (76%) 24 (55.8%) 212 (79.4%) 0 (0%) 10 (55.6%) 28 (59.6%) 62 (73.8%) 66 (79.5%) 45 (91.8%) 20 (87.0%) 5 (100%)
 Positive 74 (24%) 19 (44.2%) 55 (20.6%) 1 (100%) 8 (44.4%) 19 (40.4%) 22 (26.2%) 17 (20.5%) 4 (8.2%) 3 (13.0%) 0 (0%)
Subtype
 A 59 (19%) 1 (2.3%) 58 (21.7%) 0 (0%) 5 (27.8%) 9 (19.1%) 18 (21.4%) 16 (19.3%) 10 (20.4%) 1 (4.3%) 0 (0%)
 B 83 (27%) 2 (4.7%) 81 (30.3%) 0 (0%) 5 (27.8%) 14 (29.8%) 20 (23.8%) 20 (24.1%) 16 (32.7%) 8 (34.8%) 0 (0%)
 HER2 74 (24%) 19 (44.2%) 55 (20.6%) 1 (100%) 8 (40.4%) 19 (40.5%) 22 (26.2%) 17 (20.5%) 4 (8.2%) 3 (13%) 0 (0%)
 TN 94 (30%) 21 (48.8%) 73 (27.4%) 0 (0%) 0 (0%) 5 (10.6%) 24 (28.6%) 30 (36.1%) 19 (38.7%) 11 (47.9%) 5 (100%)
Size
 T1/T2 111 (36%) 13 (30.2%) 98 (36.7%) 1 (100%) 17 (94.4%) 28 (59.6%) 42 (50.0%) 21 (25.3%) 2 (4.1%) 0 (0%) 0 (0%)
 T3/T4 199 (64%) 30 (69.8%) 169 (63.3%) 0 (0%) 1 (5.6%) 19 (40.4%) 42 (50.0%) 62 (74.7%) 47 (95.9%) 23 (100%) 5 (100%)
Axilla
 Negative 82 (26%) 15 (34.9%) 67 (25.1%) 1 (100%) 12 (66.7%) 24 (51.1%) 24 (28.6%) 11 (13.3%) 9 (18.4%) 1 (4.3%) 0 (0%)
 N1 138 (45%) 21 (48.8%) 117 (43.8%) 0 (0%) 5 (27.8%) 19 (40.4%) 37 (44.0%) 45 (54.2%) 22 (44.9%) 8 (34.8%) 2 (40%)
 N2/N3 90 (29%) 7 (16.3%) 83 (31.1%) 0 (0%) 1 (5.6%) 4 (8.5%) 23 (27.4%) 27 (32.5%) 18 (36.7%) 14 (60.9%) 3 (60%)
Stage
 I/II 117 (38%) 18 (41.9%) 99 (37.1%) 1 (100%) 16 (88.9%) 32 (68.1%) 42 (50.0%) 21 (25.3%) 5 (10.2%) 0 (0%) 0 (0%)
 III 193 (62%) 25 (58.1%) 168 (62.9%) 0 (0%) 2 (11.1%) 15 (31.9%) 42 (50.0%) 62 (74.7%) 44 (89.8%) 23 (100%) 5 (100%)
  1. apCR pathological complete response
\